CA3223130A1 - Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency - Google Patents

Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency Download PDF

Info

Publication number
CA3223130A1
CA3223130A1 CA3223130A CA3223130A CA3223130A1 CA 3223130 A1 CA3223130 A1 CA 3223130A1 CA 3223130 A CA3223130 A CA 3223130A CA 3223130 A CA3223130 A CA 3223130A CA 3223130 A1 CA3223130 A1 CA 3223130A1
Authority
CA
Canada
Prior art keywords
piperidine
trifluoromethyl
carboxylic acid
phenyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3223130A
Other languages
English (en)
French (fr)
Inventor
Nigel Ramsden
David John Fox
James Andrew HUNTINGTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centessa Pharmaceuticals UK Ltd
Original Assignee
Centessa Pharmaceuticals UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centessa Pharmaceuticals UK Ltd filed Critical Centessa Pharmaceuticals UK Ltd
Publication of CA3223130A1 publication Critical patent/CA3223130A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3223130A 2021-06-15 2022-06-15 Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency Pending CA3223130A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2108523.8A GB202108523D0 (en) 2021-06-15 2021-06-15 Compositions and their use for the treatment of alpha1-antitrypsin deficiency
GB2108523.8 2021-06-15
PCT/GB2022/051502 WO2022263816A1 (en) 2021-06-15 2022-06-15 COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
CA3223130A1 true CA3223130A1 (en) 2022-12-22

Family

ID=76954605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3223130A Pending CA3223130A1 (en) 2021-06-15 2022-06-15 Compositions and their use for the treatment of .alpha.1-antitrypsin deficiency

Country Status (12)

Country Link
US (1) US20240197707A1 (https=)
EP (1) EP4355328A1 (https=)
JP (1) JP7854001B2 (https=)
KR (1) KR20240027693A (https=)
CN (1) CN117794538A (https=)
AU (1) AU2022295130A1 (https=)
BR (1) BR112023026510A2 (https=)
CA (1) CA3223130A1 (https=)
GB (1) GB202108523D0 (https=)
IL (1) IL309355A (https=)
MX (1) MX2023015398A (https=)
WO (1) WO2022263816A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918410D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071621C (en) 1991-06-19 1996-08-06 Ahihiko Hosoda Aldehyde derivatives
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
US8258158B2 (en) 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
WO2012097371A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis
MX2020013853A (es) 2018-06-22 2021-05-27 Ucl Business Ltd Compuestos innovadores.
CA3114672A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Also Published As

Publication number Publication date
JP7854001B2 (ja) 2026-04-30
MX2023015398A (es) 2024-04-29
CN117794538A (zh) 2024-03-29
JP2024523406A (ja) 2024-06-28
EP4355328A1 (en) 2024-04-24
WO2022263816A1 (en) 2022-12-22
IL309355A (en) 2024-02-01
GB202108523D0 (en) 2021-07-28
US20240197707A1 (en) 2024-06-20
KR20240027693A (ko) 2024-03-04
BR112023026510A2 (pt) 2024-03-05
AU2022295130A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
US12221422B2 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
US12611402B2 (en) Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency
US12286402B2 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
US20240197707A1 (en) Compositions and their Use for the Treatment of A1-Antitrypsin Deficiency
EP4073043B1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40079913A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40079913B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2021116710A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY
WO2022263817A1 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40076778A (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
HK40076778B (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251205

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260202

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205